Explore 3 Stock Ideas & Industry Insights Download Free Report

Affimed N.V.

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
2600
Market Cap
0.00M

Momentum Score

…

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Affimed N.V. is a clinical-stage immuno-oncology company developing innate cell engager therapies designed to recruit and activate natural killer cells and macrophages to kill cancer cells. Long-term growth drivers include clinical progression of its pipeline, potential licensing or partnership deals for its bispecific platform, and increasing interest in innate immune approaches within oncology. The platform's differentiated mechanism and multiple development programs may benefit investors seeking exposure to novel immunotherapies.

The company faces high development and regulatory risk, likely need for external financing with dilution risk, and significant competitive pressure in the immuno-oncology sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
5.64M
Revenue Per Share
0.37
Gross Profit TTM
5.64M
Debt / Equity
-
ROE
-149.49%
Net Debt
-
ROCE
-155.98%
Diluted EPS TTM
-5.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Income before tax -105.94M -86.00M -57.52M
Net income -105.94M -86.00M -57.52M
Selling general administrative 24.68M 32.08M 24.22M
Reconciled depreciation 1.75M 2.90M 1.33M
Operating income -111.14M -88.97M -65.00M
Interest expense 1.81M 1.63M 0.71M
Tax provision 0.00M 0.00M 0.00M
Interest income 0.51M 0.00M 0.00M
Net interest income 0.24M -1.27M -1.13M
Total revenue 8.28M 41.35M 40.37M
Total operating expenses 119.41M 130.33M 105.36M
Total other income expense net 4.96M 4.24M 8.60M
Net income from continuing ops -105.94M -86.00M -57.52M
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 97.16M 200.51M 225.13M
Intangible assets 0.03M 0.06M 1.61M
Other current assets 5.50M 2.46M 3.53M
Total liab 39.35M 47.60M 89.18M
Total stockholder equity 57.81M 152.91M 135.95M
Capital stock 1.50M 1.49M 1.23M
Retained earnings -536.13M -430.19M -333.40M
Cash 38.53M 190.29M 197.63M
Total current liabilities 25.91M 34.65M 64.55M
Short long term debt 5.83M 5.93M 0.58M
Total current assets 84.19M 196.07M 206.39M
Long term investments - 0.00M 12.35M
Short term investments 34.37M 0.00M -
Net receivables 5.33M 2.70M 4.81M
Long term debt 6.32M 11.69M 17.06M
Inventory 0.46M 0.63M 0.42M
Accounts payable 18.92M 19.08M 18.86M
Non current assets total 12.97M 4.44M 18.74M
Capital lease obligations 7.20M 0.57M 1.05M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -33.31M 6.30M 0.00M -
Net borrowings -6.42M -1.31M 16.84M -
Total cash from financing activities -6.22M 88.56M 133.58M -
Net income -105.94M -86.00M -57.52M -41.37M
Change in cash -152.55M -10.73M 43.14M -
Begin period cash flow 190.29M 197.63M 146.85M -
End period cash flow 38.53M 190.29M 197.63M 146.85M
Total cash from operating activities -110.27M -104.89M -86.59M -
Issuance of capital stock 0.23M 95.91M 124.46M -
Depreciation 1.75M 2.90M 1.33M -
Change to inventory 0.10M -0.21M -0.17M -
Capital expenditures 3.73M 0.70M 3.85M 0.00M
Change in working capital -12.16M -38.07M -34.81M -
Stock based compensation 10.71M 19.11M 11.82M -
Other non cash items -0.73M -2.12M -6.51M -
Free cash flow -114.00M -105.59M -90.44M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AFMDQ
Affimed N.V.
-
-%
0.00 - - 0.00 - 13.07 1.13
NVO
Novo Nordisk A/S
-0.34
0.86%
39.09 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.95
1.30%
529.50 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-18.50
1.96%
927.03 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165

49 621 560030

76

Name Title Year Born
Dr. Wolfgang Fischer Ph.D. MD, COO, Chief Strategy Officer & Member of Management Board 1964
Dr. Andreas Harstrick M.D. Chief Medical Officer & Member of Management Board 1961
Prof. Melvyn Little Founder & Consultant NA
Mr. Michael Wolf Head of Finance & Administration 1967
Mr. Alexander Fudukidis Head of Investor Relations & Director of Investor Relations NA
Mary Beth Sandin Vice President of Marketing & Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…